Effect of Resistance Training on Musculoskeletal Endocrine Interactions (COMB)

April 16, 2015 updated by: Lynae J. Hanks, PhD. RD, University of Alabama at Birmingham

Communications of Muscle and Bone

This project will evaluate the impact of resistance training on the synthesis and release of hormones and growth factors from the musculoskeletal system and the extent to which the communicative capacity influences glucose homeostasis In turn, the contribution of glucose regulation on the musculoskeletal system will also be evaluated. This small study will serve as a pilot/feasibility study to define a protocol for implementation of a resistance training intervention in the pediatric population. To establish feasibility, this study population is limited to overweight African American boys ages 7-11 years.

In light of well-established accolades of resistance training, historical recommendations for avoidance among the pediatric population have deterred implementation of resistance training interventions in young adolescents. However, contemporary data indicating a profound benefit of resistance training to the skeletal system in pre-adolescents has led to the Academy of Sports Medicine, as well as various other pediatric health interest groups, to support supervised programs incorporating resistance training in young children, emphasizing large muscle and core strengthening. To date, such trials have not been conducted in the pediatric population

Study Overview

Detailed Description

Early adolescence (pre-puberty) is associated with many physiological changes with the intersection of metabolic pathways and body composition at the core. Lifestyle behaviors provide substantial influence and the rise of sedentary behavior particularly among this population can exert profound disruption. Metabolic dysfunction associated with limited activity and thus limited strain on the muscles and bones is associated with poor musculoskeletal health. Metabolic disturbance within the system during critical periods of development such as pre-puberty confers long-term health consequences.

Communication across systems is reliant upon various hormones which interact on the regulation of glucose homeostasis, bone metabolism, and muscle development. While it is well-established that bone and muscle growth are dependent upon fuel utilization, factors secreted by bone and muscle have been recently shown to play an interactive role in glucose homeostasis. Data derived primarily from animal models have demonstrated maintenance of physiological levels promote optimal growth and development, whereas these hormones appear to have adverse effects when levels are altered. While the data in animals is compelling, translation in humans has not been conducted.

Speculatively, impaired glucose homeostasis, much attributable to decreased strain on the musculoskeletal system, promotes impairments in physiological roles of these hormones. As a result, disordered development may be of consequence, such that the bones grow bigger yet have impaired quality, and delivery of fuel to muscle is compromised. Obesity-induced perturbations in metabolism and tissue partitioning may be an added stress to the system, impairing muscle function, power, performance and overall quality. Strategies that optimize the protective effects of the musculoskeletal system may be encompassed by forced stress on the system via resistance training, known to influence synthesis and release of hormones involved in fuel delivery and utilization by muscle and bone. The strategy proposed will target optimization of musculoskeletal health, promoting synthesis and release of musculoskeletal-derived signals providing protection on metabolic health at a critical period of development.

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama at Birmingham

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

7 years to 12 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • overweight
  • early pubertal boys (Tanner stage <3)
  • ages 7-12 years
  • self-identified as Non-Hispanic Black.

Exclusion Criteria:

  • type 1 or 2 diabetes
  • musculoskeletal disorders
  • disturbances in glucose or lipid metabolism
  • use of thyroid medication, diuretics, beta-blockers, or any medication that potentially could affect body composition, the lipid profile, insulin sensitivity, or blood pressure
  • allergy to EMLA cream
  • history of eating disorders, cancer, kidney disease, endocrinopathy, liver disease, heart disease, or thyroid disease
  • medically determined not to be able to engage in resistance training

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Non-Resistance Trained
No Participation in Resistance Training
No supervised strength training throughout the study
Experimental: Resistance Trained
Participation in Resistance Training
Supervised strength training 3 days per week for 24 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting plasma FGF-23 concentration
Time Frame: 0,8,12,16, 24 weeks
Fibroblast Growth Factor-23
0,8,12,16, 24 weeks
Fasting serum osteocalcin concentration
Time Frame: 0, 8, 12, 16, 24 weeks
0, 8, 12, 16, 24 weeks
Fasting serum insulin concentration
Time Frame: 0, 8, 12, 16, 24 weeks
0, 8, 12, 16, 24 weeks
Fasting serum glucose concentration
Time Frame: 0, 8, 12, 16, 24 weeks
0, 8, 12, 16, 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone mineral content
Time Frame: 0, 12, 24 weeks
by DXA
0, 12, 24 weeks
Muscle strength
Time Frame: 0, 8, 12, 16, 24 weeks
0, 8, 12, 16, 24 weeks
Muscle density
Time Frame: 0, 12, 24 weeks
by pQCT
0, 12, 24 weeks
Bone stress-strain index
Time Frame: 0, 12, 24 weeks
by pQCT
0, 12, 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting energy expenditure
Time Frame: 0, 12, 24 weeks
by indirect calorimetry
0, 12, 24 weeks
Total fat mass
Time Frame: 0, 12, 24 weeks
by DXA
0, 12, 24 weeks
Total lean mass
Time Frame: 0, 12, 24 weeks
by DXA
0, 12, 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Orlando M Gutierrez, MD, MMSc, University of Alabama at Birmingham
  • Principal Investigator: Lynae J Hanks, PhD, RD, University of Alabama at Birmingham
  • Study Director: Krista Casazza, PhD, RD, University of Alabama at Birmingham
  • Study Director: Marcas Bamman, PhD, University of Alabama at Birmingham
  • Study Chair: Ambika Ashraf, MD, University of Alabama at Birmingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2013

Primary Completion (Actual)

September 1, 2014

Study Completion (Actual)

September 1, 2014

Study Registration Dates

First Submitted

December 10, 2013

First Submitted That Met QC Criteria

January 15, 2014

First Posted (Estimate)

January 20, 2014

Study Record Updates

Last Update Posted (Estimate)

April 17, 2015

Last Update Submitted That Met QC Criteria

April 16, 2015

Last Verified

April 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • COMB

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Musculoskeletal and Metabolic Crosstalk

Clinical Trials on No Resistance Training

3
Subscribe